<DOC>
	<DOC>NCT00836654</DOC>
	<brief_summary>The study will be performed to obtain further efficacy and safety data in order to obtain a marketing authorization (pivotal study). In addition, health economic data are to be collected.</brief_summary>
	<brief_title>Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group</brief_title>
	<detailed_description />
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Antibodies, Bispecific</mesh_term>
	<criteria>histological confirmed diagnosis cancer symptomatic malignant ascites EpCAM positive tumor EOCG 02 negative pregnancy acute or chronic infection exposure to investigational product, cancer chemo or radiotherapy within the last 28 days previous treatment with mouse monoclonal antibodies known or suspected hypersensitivity to Removab or similar antibodies inadequate renal function inadequate hepatic function (AST, ALt, GTP,&lt; x ULN; bilirubin &lt;1.5xULN) Platelets &gt; 80000 cells/mm3; absolute neutrophil count (ANC) &lt; 1500 cells/mm3 BMI &lt; 17 Patients with reduced nutritional status Ileus within the last 30 days Brain metastases in cancer history Pregnant and nursing women history of myocardial infarction, congestive heart failure or relevant cardiac arrhythmia within previous 3 months inadequate respiratory function in option of investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>EpCAM positive tumor</keyword>
	<keyword>malignant ascites</keyword>
	<keyword>intraperitoneal</keyword>
</DOC>